MediPharm Labs Corp.

TSE: LABS


Canadian symbol: LABS.TO
US symbol: MEDIF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 29.81M
Enterprise Value 17.98M
Trailing P/E 187.00
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)0.75
Price/Book (mrq)0.51
Enterprise Value/Revenue 0.64
Enterprise Value/EBITDA -1.08

Trading Information

Stock Price History

Beta (5Y Monthly) 1.09
52-Week Change 3-6.25%
S&P500 52-Week Change 316.57%
52 Week High 30.1000
52 Week Low 30.0550
50-Day Moving Average 30.0760
200-Day Moving Average 30.0746

Share Statistics

Avg Vol (3 month) 3275.23k
Avg Vol (10 day) 3157.82k
Shares Outstanding 5397.47M
Implied Shares Outstanding 6397.47M
Float 8377.97M
% Held by Insiders 15.13%
% Held by Institutions 15.11%
Shares Short (Sept 14, 2023) 41.14M
Short Ratio (Sept 14, 2023) 42.83
Short % of Float (Sept 14, 2023) 4N/A
Short % of Shares Outstanding (Sept 14, 2023) 40.29%
Shares Short (prior month Aug 14, 2023) 41.16M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2022
Most Recent Quarter (mrq)Jun 29, 2023

Profitability

Profit Margin -68.29%
Operating Margin (ttm)-80.51%

Management Effectiveness

Return on Assets (ttm)-18.65%
Return on Equity (ttm)-30.30%

Income Statement

Revenue (ttm)28.3M
Revenue Per Share (ttm)0.10
Quarterly Revenue Growth (yoy)119.70%
Gross Profit (ttm)N/A
EBITDA -20.44M
Net Income Avi to Common (ttm)-19.33M
Diluted EPS (ttm)-0.0700
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)15.23M
Total Cash Per Share (mrq)0.04
Total Debt (mrq)2.91M
Total Debt/Equity (mrq)4.94%
Current Ratio (mrq)3.68
Book Value Per Share (mrq)0.15

Cash Flow Statement

Operating Cash Flow (ttm)-13.64M
Levered Free Cash Flow (ttm)-6.25M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
LABS.TO
MediPharm Labs
24 minutes ago
LABS.TO
MediPharm Labs
3 days ago
LABS.TO
MediPharm Labs
4 days ago
LABS.TO
MediPharm Labs
5 days ago
LABS.TO
MediPharm Labs
1 week ago
LABS.TO
MediPharm Labs
1 week ago
LABS.TO
MediPharm Labs
1 week ago
LABS.TO
MediPharm Labs
3 weeks ago
LABS.TO
MediPharm Labs
4 weeks ago
LABS.TO
MediPharm Labs
1 month ago
LABS.TO
MediPharm Labs
1 month ago
LABS.TO
MediPharm Labs
1 month ago
LABS.TO
MediPharm Labs
1 month ago
LABS.TO
MediPharm Labs
2 months ago
LABS.TO
MediPharm Labs
2 months ago
LABS.TO
MediPharm Labs
2 months ago
LABS.TO
MediPharm Labs
2 months ago
LABS.TO
MediPharm Labs
2 months ago
LABS.TO
MediPharm Labs
2 months ago
LABS.TO
MediPharm Labs
3 months ago
LABS.TO
MediPharm Labs
4 months ago
LABS.TO
MediPharm Labs
6 months ago
LABS.TO
MediPharm Labs
6 months ago
LABS.TO
MediPharm Labs
6 months ago
LABS.TO
MediPharm Labs
6 months ago
LABS.TO
MediPharm Labs
7 months ago
LABS.TO
MediPharm Labs
7 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
10 months ago
LABS.TO
MediPharm Labs
10 months ago
LABS.TO
MediPharm Labs
10 months ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago
LABS.TO
MediPharm Labs
4 years ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Sep 2023)Next Qtr. (Dec 2023)Current Year (2023)Next Year (2024)
No. of Analysts2222
Avg. Estimate00-0.02-0.01
Low Estimate-0.01-0.01-0.04-0.04
High Estimate00-0.010.02
Year Ago EPS-0.03-0.02-0.11-0.02
Revenue EstimateCurrent Qtr. (Sep 2023)Next Qtr. (Dec 2023)Current Year (2023)Next Year (2024)
No. of Analysts2222
Avg. Estimate10.37M10.94M36.72M49.62M
Low Estimate9.9M10.3M35.6M45.4M
High Estimate10.83M11.58M37.84M53.83M
Year Ago SalesN/A5.62M22.12M36.72M
Sales Growth (year/est)N/A94.80%66.00%35.10%
Earnings History2022-09-292022-12-302023-03-302023-06-29
EPS Est.-0.02-0.01-0.01-0.01
EPS Actual-0.03-0.02-0.01-0.01
Difference-0.01-0.0100
Surprise %-50.00%-100.00%0.00%0.00%
EPS TrendCurrent Qtr. (Sep 2023)Next Qtr. (Dec 2023)Current Year (2023)Next Year (2024)
Current Estimate00-0.02-0.01
7 Days Ago00-0.02-0.01
30 Days Ago00-0.02-0.01
60 Days Ago-0.01-0.01-0.04-0.03
90 Days Ago-0.01-0.01-0.04-0.03
EPS RevisionsCurrent Qtr. (Sep 2023)Next Qtr. (Dec 2023)Current Year (2023)Next Year (2024)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesLABS.TOIndustrySector(s)S&P 500
Current Qtr.100.00%N/AN/AN/A
Next Qtr.100.00%N/AN/AN/A
Current Year81.80%N/AN/AN/A
Next Year50.00%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
5.13%% of Shares Held by All Insider
5.11%% of Shares Held by Institutions
5.39%% of Float Held by Institutions
2Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Captrust Financial Advisors1,850Jun 29, 20220.00%138

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Amplify Seymour Cannabis ETF2,934,844Jul 30, 20230.75%220,113
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by MediPharm Labs Corp.


MediPharm Labs Launches new GMP Products to the Australian Medical Cannabis Market

MediPharm Labs Launches new GMP Products to the Australian Medical Cannabis Market

The launch includes GMP strain-specific full spectrum cannabis oil and inhalation cartridge products to be distributed to patients under the MediPharm Labs Beacon Medical brand.  As of July 2023, all Australian medical cannabis products must meet strict pharmaceutical GMP standards. MediPharm Labs is one of the few companies already meet... Read More...
MediPharm Labs Improves Domestic Sales Gross Margin with Termination of Shelter Cannabis Brands Royalty Agreement

MediPharm Labs Improves Domestic Sales Gross Margin with Termination of Shelter Cannabis Brands Royalty Agreement

MediPharm Labs and Shelter Cannabis Brands have terminated their royalty agreement with a one-time cash payment. Agreement includes the elimination of ongoing royalty payments, for a one-time lump sum payment. TORONTO, Sept. 20, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a company s... Read More...
MediPharm Labs Completes Sale of Vacant Land for Cash Proceeds of $1.9 million

MediPharm Labs Completes Sale of Vacant Land for Cash Proceeds of $1.9 million

MediPharm Labs sold vacant land in Napanee, Ontario last utilized in 2021 for outdoor cannabis growing activities. The land was acquired by MediPharm as part of the VIVO Cannabis acquisition in April 2023. The net cash proceeds of $1.9 million adds non-dilutive capital to MediPharm's strong balance sheet. The $1.9 million cash is in addi... Read More...
MediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

MediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

MediPharm Labs wholly owned subsidiary Harvest Medicine has published a study in the peer-reviewed American Journal of Endocannabinoid Medicine. This is the largest peer reviewed published study of its kind on Fibromyalgia and cannabis, with over 800 patient assessments. Between baseline and follow-up appointments, 75% of patients saw a ... Read More...
MediPharm Labs Reports Second Quarter Results with Doubling of Revenue and Record Margin Growth

MediPharm Labs Reports Second Quarter Results with Doubling of Revenue and Record Margin Growth

TORONTO, Aug. 14, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three months ended June 30, 2023. Second Quarter 2023 – Select Highlights Completed our first commercial d... Read More...
MediPharm Labs Sets Date to Report Second Quarter 2023 Financial Results

MediPharm Labs Sets Date to Report Second Quarter 2023 Financial Results

TORONTO, Aug. 10, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its second quarter financial results for the three month period ended June 30, 2023, before markets open on Monday,... Read More...
MediPharm Labs Makes First Delivery of Cannabis Clinical Trial Material to US Research Partner and Provides Update on US FDA Status

MediPharm Labs Makes First Delivery of Cannabis Clinical Trial Material to US Research Partner and Provides Update on US FDA Status

MediPharm announces first delivery of pharmaceutical cannabis product for NIH funded clinical trial, following import permit from the US Drug Enforcement Agency (DEA) and Health Canada export permit. MediPharm has provided a full response to the US Food and Drug Administration (FDA) in relation to the initial pre-approval site inspection... Read More...
MediPharm Labs Announces Voting Results From the 2023 Annual Meeting of Shareholders

MediPharm Labs Announces Voting Results From the 2023 Annual Meeting of Shareholders

TORONTO, June 29, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs"), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual meeting of holders of common shares ("Shareholders") held on Thursday, June 29, 2023 (the "... Read More...
MediPharm Labs Announces Change of Auditor

MediPharm Labs Announces Change of Auditor

TORONTO, June 22, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs"), a pharmaceutical company specialized in precision-based cannabinoids, today announced that, at the request of the Company's board of directors and following the recommendation of the audit committee, the Company's board of ... Read More...
MediPharm Labs Reports First Quarter Results with Growth in Sales, Margin and EBITDA

MediPharm Labs Reports First Quarter Results with Growth in Sales, Margin and EBITDA

TORONTO, May 15, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three months ended March 31, 2023. First Quarter 2023 – Select Highlights Progress Towards Profitability ... Read More...
MediPharm Labs Sets Date to Report First Quarter 2023 Financial Results

MediPharm Labs Sets Date to Report First Quarter 2023 Financial Results

TORONTO, May 10, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its first quarter financial results for the three month period ended March 31, 2023, before markets open on Monday, ... Read More...
MediPharm Labs Corp. Completes Acquisition of VIVO Cannabis Inc. and Confirms Final Ownership Ratio

MediPharm Labs Corp. Completes Acquisition of VIVO Cannabis Inc. and Confirms Final Ownership Ratio

BARRIE, ON, April 3, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", or "MediPharm Labs") and VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) ("VIVO") are pleased to announce the completion of the previously announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangem... Read More...
MediPharm Labs Sets Date to Report Fourth Quarter and Full Year 2022 Financial Results

MediPharm Labs Sets Date to Report Fourth Quarter and Full Year 2022 Financial Results

TORONTO, March 28, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three and twelve month period ended December 31, 2022 before markets open... Read More...
MediPharm Labs Corp. Announces Voting Results From Special Meeting of Shareholders

MediPharm Labs Corp. Announces Voting Results From Special Meeting of Shareholders

BARRIE, ON, March 21, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", or "MediPharm Labs") is pleased to announce that the shareholders of MediPharm (the "Shareholders") have approved the plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement"), previously announced ... Read More...
MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study

MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study

MediPharm Labs shares progress on clinical trials, including the provision of clinical trial materials and research support to multiple partners. Research support consists of both product and services for partner studies across various indications. MediPharm Labs participation ranges from full drug development support to FDA approved cli... Read More...
MediPharm Labs Corp. Announces Mailing and Filing of Joint Circular for Special Meeting of Shareholders to approve Arrangement with VIVO Cannabis Inc.

MediPharm Labs Corp. Announces Mailing and Filing of Joint Circular for Special Meeting of Shareholders to approve Arrangement with VIVO Cannabis Inc.

BARRIE, ON, Feb. 21, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", or "MediPharm Labs") is pleased to announce the mailing of a joint management information circular of MediPharm and VIVO Cannabis Inc. ("VIVO") dated February 6, 2023 (the "Circular") and related documents for the special meeting of MediPh... Read More...
MediPharm Labs Sets Date to Report Third Quarter 2022 Financial Results

MediPharm Labs Sets Date to Report Third Quarter 2022 Financial Results

BARRIE, ON, Nov. 9, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release second quarter financial results for the three and nine month period ended September 30, 2022, before markets open on Monday, Novem... Read More...
MediPharm Labs Completes Sale of Australian Facility for Proceeds of $7,250,000 AUD

MediPharm Labs Completes Sale of Australian Facility for Proceeds of $7,250,000 AUD

BARRIE, ON, Oct. 7, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, completed the sale of MediPharm Labs Australia Pty ("MediPharm Labs Australia"), a fully owned subsidiary of the Company, for a value of $7.25M AUD ($6.3M CAD) (the ... Read More...
MediPharm Labs Sets Date to Report Second Quarter 2022 Financial Results

MediPharm Labs Sets Date to Report Second Quarter 2022 Financial Results

BARRIE, ON, Aug. 11, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release second quarter financial results for the three and six month period ended June 30, 2022 before markets open on Monday, August 15, ... Read More...
MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC

MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC

MediPharm to design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life's end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites. The lead investigators have been awarded a total of US$16M grant from the US National Institutes of Health and the National ... Read More...
MediPharm Labs Awarded Payment of $9.8M in Connection to a 2020 Statement of Claim Against a Previous Customer

MediPharm Labs Awarded Payment of $9.8M in Connection to a 2020 Statement of Claim Against a Previous Customer

BARRIE, ON, July 27, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, today announced that it has been awarded a favourable summary of judgement in the Ontario Court of Justice in connection with a supply agreement disput... Read More...
MediPharm Labs Enters into $6.2M Purchase Agreement for the Sale of Australian Facility

MediPharm Labs Enters into $6.2M Purchase Agreement for the Sale of Australian Facility

BARRIE, ON, July 11, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, has entered into a Share Purchase Agreement (the "Agreement") with OneLife Botanicals PTY ("OneLife Botanicals") for the sale of MediPharm Labs Australia Pty Ltd ("... Read More...
MediPharm Labs Announces Voting Results From the 2022 Annual Meeting of Shareholders

MediPharm Labs Announces Voting Results From the 2022 Annual Meeting of Shareholders

BARRIE, ON, June 30, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual meeting of holders of common shares held on Thursday, June 30, 2022 (the "Meeting"). The voting result... Read More...
MediPharm Labs Sets Date to Report First Quarter 2022 Financial Results

MediPharm Labs Sets Date to Report First Quarter 2022 Financial Results

TORONTO, May 12, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three month period ended March 31, 2022 before markets open on Monday, May 16, 2022. MediPhar... Read More...
MediPharm Labs Names Experienced Pharma and Med Tech Executive David Pidduck, as CEO

MediPharm Labs Names Experienced Pharma and Med Tech Executive David Pidduck, as CEO

BARRIE, ON, April 20, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs", "MediPharm") a pharmaceutical company specializing in precision-based cannabinoids, today announced that it has appointed experienced Pharma and Med Tech executive David Pidduck as Chief Executive Officer and Director of the Company.... Read More...
MediPharm Labs Reports Fourth Quarter and Full Year 2021 Results

MediPharm Labs Reports Fourth Quarter and Full Year 2021 Results

TORONTO, March 31, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and twelve months ended December 31, 2021. 2021 – Select Operating Highlights Expanded internation... Read More...
MediPharm Labs Sets Date to Report Fourth Quarter and Full Year 2021 Financial Results

MediPharm Labs Sets Date to Report Fourth Quarter and Full Year 2021 Financial Results

TORONTO, March 29, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three and twelve month period ended December 31, 2021 after markets close on Thursday, Marc... Read More...
MediPharm Labs Strengthens Recreational Business Adding Flower and Pre-Rolls to Portfolio

MediPharm Labs Strengthens Recreational Business Adding Flower and Pre-Rolls to Portfolio

Known for its high-quality, specialty recreational dried flower products, Shelter Cannabis is expected to complement MediPharm's existing Canadian cannabis portfolio. Adds IP and well-regarded Shelter brands Wildlife and Shelter Craft to MediPharm. MediPharm expects to leverage its recently expanded national sales network to drive Shelte... Read More...
MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

Completed a Drug Master File ("DMF") process for CBD Active Pharmaceutical Ingredient ("API") for the US Federal Drug Administration ("FDA"). Use of Canadian Drug Establishment Licence ("DEL") to register API with the FDA for commercial opportunities in pharmaceutical development, novel drugs and generic drugs. The cannabis-based drug ... Read More...
MediPharm Labs Provides Operational Update and Confirms Profitability Improvement Initiatives are Underway

MediPharm Labs Provides Operational Update and Confirms Profitability Improvement Initiatives are Underway

Strong cash balance and continued reduction of convertible debt to less than $500K.Opportunities for optimization of the operating strategy between Australia and Canada as the Canadian Drug Establishment Licence (DEL) unlocks many manufacturing and supply chain pathways. These pathways will reduce infrastructure cost, improve delivery tim... Read More...
MediPharm Labs Announces Changes to Board of Directors

MediPharm Labs Announces Changes to Board of Directors

BARRIE, Ontario, Dec. 07, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce changes to its Board of Directors (the “Board”). Effectively immediately, Pat McCutcheon, Warren Everitt and Keith Str... Read More...
MediPharm Reports Third Quarter 2021 Results; Announces New CEO to Start Today

MediPharm Reports Third Quarter 2021 Results; Announces New CEO to Start Today

BARRIE, Ontario, Nov. 15, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids today announced its financial results for the three and nine months ended September 30, 2021, a period of transition in establishing itself as an i... Read More...
MediPharm Labs Completes a New Cannabis Oil Delivery to German Partner Vayamed

MediPharm Labs Completes a New Cannabis Oil Delivery to German Partner Vayamed

New strategic partnership through the delivery of GMP extract to Germany for Vayamed, the medical cannabis business unit of Sanity GroupVayamed is a well-established operating medical cannabis company in Germany, where the medical cannabis market is expected to be worth €7.7 billion by 2028 according to Forbes BARRIE, Ontario, Oct. 19, 20... Read More...
Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent

Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent

McMaster University researchers using MediPharm Labs’ CBD50 formula and a CBD:THC 10:2 formulation, which has the same cannabinoid ratio as MediPharm Labs’ CBD25:, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-controlled trial using cannabis- oil for treatment of insomnia in major ... Read More...
MediPharm Labs Australia Receives Government Grant to Assist with International Expansion

MediPharm Labs Australia Receives Government Grant to Assist with International Expansion

Received first instalment of a government grant for $330,000AUD as part of the Australian government’s Manufacturing Modernisation program aimed at supporting manufacturers scaling their businesses.Grant to be used for automation of downstream manufacturing and scaling purification abilities.Government grant as part of broader manufacturi... Read More...
MediPharm Labs Receives Export Authorization to Ship Medical Cannabis to Brazil

MediPharm Labs Receives Export Authorization to Ship Medical Cannabis to Brazil

Completed the regulatory process required to ship medical cannabis to Brazil with import permits issued from ANVISA and export permits issued from Health Canada. Initial deliveries will be under the compassionate care program.First shipments to Brazil to be used for patient trials to collect data that may be used in future product marketi... Read More...
MediPharm Reports Second Quarter 2021 Results and Advances Pharmaceutical Strategy; Announces new Board Chair

MediPharm Reports Second Quarter 2021 Results and Advances Pharmaceutical Strategy; Announces new Board Chair

BARRIE, Ontario, Aug. 16, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in research-driven development and manufacturing of cannabis API and finished dose products today announced its financial results for the three and six months ended June 30, 2021,... Read More...
MediPharm Labs Achieves Major Pharmaceutical Manufacturing Milestone: Receives Canadian GMP Pharmaceutical Drug Establishment Licence

MediPharm Labs Achieves Major Pharmaceutical Manufacturing Milestone: Receives Canadian GMP Pharmaceutical Drug Establishment Licence

Health Canada Drug Establishment Licence allows MediPharm Labs to conduct pharmaceutical manufacturing and sale of Active Pharmaceutical Ingredients and Pharmaceutical Drug ProductsMakes MediPharm Labs a full-service pharmaceutical company that can support the global pharma entry into the drugs containing cannabis market, including in the... Read More...
MediPharm Labs Enters Research Agreement with McMaster University to Develop Drugs Containing Cannabis Candidates

MediPharm Labs Enters Research Agreement with McMaster University to Develop Drugs Containing Cannabis Candidates

MediPharm Labs’ Cannabis Drug Licence and expertise qualifies and positions the Company to supply clinical trial material, assist in investigation protocol and provide regulatory support for multiple trialsThree initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD drug candidates for multiple indicat... Read More...
Coming Soon.
IndexLast% Change
S&P 5004,288.05--
Euro STOXX 504,161.210.32%Negative
FTSE 1007,569.060.51%Negative
Nikkei 22531,759.880.31%Negative

Delayed data (1h)
IndexLast% Change
S&P 5004,288.05--
Euro STOXX 504,161.210.32%Negative
FTSE 1007,569.060.51%Negative
Nikkei 22531,759.880.31%Negative


Share this page